Basit öğe kaydını göster

dc.contributor.authorBerber, Engin
dc.contributor.authorÇanakoğlu, Nurettin
dc.contributor.authorTonbak, Şükrü
dc.contributor.authorÖzdarendeli, Aykut
dc.date.accessioned2021-11-01T06:23:52Z
dc.date.available2021-11-01T06:23:52Z
dc.date.issued2021en_US
dc.identifier.citation[1]E. Berber, N. Çanakoğlu, Ş. Tonbak, A. Ozdarendeli, Development of a protective inactivated vaccine against Crimean–Congo hemorrhagic fever infection, Heliyon. 7 (2021) e08161. doi:10.1016/j.heliyon.2021.e08161.en_US
dc.identifier.issn2405-8440
dc.identifier.otherPMID: 34703927
dc.identifier.urihttps://doi.org/10.1016/j.heliyon.2021.e08161
dc.identifier.urihttps://hdl.handle.net/20.500.12809/9613
dc.description.abstractCrimean-Congo hemorrhagic fever (CCHF) is an emerging zoonotic infectious disease caused by Crimean-Congo hemorrhagic fever virus (CCHFV). The first clinical CCHF infection was described in 1944 in the Crimean Peninsula, exclusively in humans, with case-fatality rates exceeding 30%. The increasing number of cases, high mortality rate, and lack of effective therapy make CCHF a serious threat to public health and a potential bioterrorism agent. The present study evaluated the development, immunogenicity, and immune response durations for cell-culture-derived inactivated vaccine (CCVax) formulations in comparison with those of mouse-brain-derived vaccine (MBVax) formulations. In this study, the Kelkit06 CCHF virus strain was propagated in both suckling mice and Vero E6 cells, and purified with a sucrose gradient. Formalin-inactivated vaccine candidates were formulated at various doses [low dose (LD), 5 μg; medium dose (MD), 10 μg; high dose (HD), 20 μg)] and mixed with an alum adjuvant. BALB/c mice received the same doses of the vaccine formulations three times at 3-week intervals. The humoral endpoint IgG responses were evaluated and compared for the MBVax and CCVax treatments. The duration of the presence of IgG and neutralizing antibody (Ab) titers was evaluated and compared until up to 1 year after immunization. The humoral IgG responses indicated that the CCVax and MBVax candidates enhanced the IgG endpoint titers in a dose-dependent manner, which were induced more strongly in all the CCVax groups than in the MBVax mice. The fold changes in neutralizing Ab levels were also found to be higher in the CCVax groups: between 2- and 7.6-fold after the second week of the last immunization. The neutralization titers peaked 4 months after immunization in all the vaccine-receiving groups, but these were still comparable at the end of the first year. The CCVax formulations induced higher IgG and neutralizing Ab titers at all the measured time points. In this study, we showed that cell-culture-purified and formalin-inactivated vaccine candidates induced strong and robust immunity in vaccinated mice dose-dependently, more so than mouse-brain-derived vaccines.en_US
dc.item-language.isoengen_US
dc.publisherscienceDirecten_US
dc.relation.isversionof10.1016/j.heliyon.2021.e08161en_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCrimean–Congo hemorrhagic fever virusen_US
dc.subjectBunyavirusen_US
dc.subjectHemorrhagic feveren_US
dc.subjectInactivated vaccineen_US
dc.subjectProtective responseen_US
dc.subjectLong-term immunityen_US
dc.subjectHumoral immune responseen_US
dc.titleDevelopment of a protective inactivated vaccine against Crimean-Congo hemorrhagic fever infectionen_US
dc.item-typearticleen_US
dc.contributor.departmentMÜ, Milas Veteriner Fakültesi, Klinik Öncesi Bilimler Bölümüen_US
dc.contributor.authorID0000-0002-0252-2377en_US
dc.contributor.institutionauthorÇanakoğlu, Nurettin
dc.identifier.volume7en_US
dc.identifier.issue10en_US
dc.relation.journalHeliyonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster